|Dr. Jonathan C. Javitt M.D., M.P.H.||Co-Founder, Chief Scientist & Director||377.29k||N/A||1957|
|Mr. Robert Besthof M.I.M.||Head of Operations, Chief Commercial & Patient Officer||264k||N/A||1966|
|Mr. Stephen H. Willard Esq.||CEO & Director||N/A||N/A||1961|
|Prof. Daniel C. Javitt||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Seth L. Van Voorhees Ph.D.||CFO & Treasurer||N/A||N/A||1961|
|Suzanne Messere||Investor Relations||N/A||N/A||N/A|
|Dr. Michael Kunz||Gen. Counsel & Corp. Sec.||N/A||N/A||1965|
|Ms. Molly Cogan||Sr. Director of Global Communications & Gov. Affairs||N/A||N/A||N/A|
|Dr. Philip T. Lavin Ph.D.||Chief Methodologist||N/A||N/A||1947|
|Dr. Dennis K. McBride Ph.D.||Chief Strategy Officer & Sr. Scientist||N/A||N/A||N/A|
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.